Home Healthcare Biotechnology Pediatric Vaccines Market

Pediatric Vaccines Market Size, Share & Trends Analysis Report By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, Others), By Application (Infectious Disease, Cancer, Allergy, Pneumococcal Diseases, Influenza, Measles, Mumps, and Rubella (MMR), Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: April 02, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Pediatric Vaccines Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Monovalent
    2. Multivalent
  2. Pediatric Vaccines Market, By Technology 2022-2034 (USD MILLION/ Units)
    1. Live Attenuated Vaccines
    2. Inactivated Vaccines
    3. Subunit Vaccines
    4. Toxoid Vaccines
    5. Conjugate Vaccines
    6. Others
  3. Pediatric Vaccines Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Infectious Disease
    2. Cancer
    3. Allergy
    4. Pneumococcal Diseases
    5. Influenza
    6. Measles, Mumps, and Rubella (MMR)
    7. Others
  4. Regional Pediatric Vaccines Market
    1. North America
      1. North America Pediatric Vaccines Market By Type 2022-2034 (USD MILLION/ Units)
        1. Monovalent
        2. Multivalent
      2. North America Pediatric Vaccines Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Live Attenuated Vaccines
        2. Inactivated Vaccines
        3. Subunit Vaccines
        4. Toxoid Vaccines
        5. Conjugate Vaccines
        6. Others
      3. North America Pediatric Vaccines Market By Application 2022-2034 (USD MILLION/ Units)
        1. Infectious Disease
        2. Cancer
        3. Allergy
        4. Pneumococcal Diseases
        5. Influenza
        6. Measles, Mumps, and Rubella (MMR)
        7. Others
      4. U.S.
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      5. Canada
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
    2. Europe
      1. Europe Pediatric Vaccines Market By Type 2022-2034 (USD MILLION/ Units)
        1. Monovalent
        2. Multivalent
      2. Europe Pediatric Vaccines Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Live Attenuated Vaccines
        2. Inactivated Vaccines
        3. Subunit Vaccines
        4. Toxoid Vaccines
        5. Conjugate Vaccines
        6. Others
      3. Europe Pediatric Vaccines Market By Application 2022-2034 (USD MILLION/ Units)
        1. Infectious Disease
        2. Cancer
        3. Allergy
        4. Pneumococcal Diseases
        5. Influenza
        6. Measles, Mumps, and Rubella (MMR)
        7. Others
      4. U.K.
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      5. Germany
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      6. France
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      7. Spain
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      8. Italy
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      9. Russia
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      10. Nordic
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      11. Benelux
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      12. Rest of Europe
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
    3. APAC
      1. APAC Pediatric Vaccines Market By Type 2022-2034 (USD MILLION/ Units)
        1. Monovalent
        2. Multivalent
      2. APAC Pediatric Vaccines Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Live Attenuated Vaccines
        2. Inactivated Vaccines
        3. Subunit Vaccines
        4. Toxoid Vaccines
        5. Conjugate Vaccines
        6. Others
      3. APAC Pediatric Vaccines Market By Application 2022-2034 (USD MILLION/ Units)
        1. Infectious Disease
        2. Cancer
        3. Allergy
        4. Pneumococcal Diseases
        5. Influenza
        6. Measles, Mumps, and Rubella (MMR)
        7. Others
      4. China
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      5. Korea
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      6. Japan
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      7. India
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      8. Australia
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      9. Taiwan
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      10. South East Asia
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      11. Rest of Asia-Pacific
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
    4. Middle East and Africa
      1. Middle East and Africa Pediatric Vaccines Market By Type 2022-2034 (USD MILLION/ Units)
        1. Monovalent
        2. Multivalent
      2. Middle East and Africa Pediatric Vaccines Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Live Attenuated Vaccines
        2. Inactivated Vaccines
        3. Subunit Vaccines
        4. Toxoid Vaccines
        5. Conjugate Vaccines
        6. Others
      3. Middle East and Africa Pediatric Vaccines Market By Application 2022-2034 (USD MILLION/ Units)
        1. Infectious Disease
        2. Cancer
        3. Allergy
        4. Pneumococcal Diseases
        5. Influenza
        6. Measles, Mumps, and Rubella (MMR)
        7. Others
      4. UAE
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      5. Turkey
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      6. Saudi Arabia
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      7. South Africa
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      8. Egypt
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      9. Nigeria
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      10. Rest of MEA
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
    5. LATAM
      1. LATAM Pediatric Vaccines Market By Type 2022-2034 (USD MILLION/ Units)
        1. Monovalent
        2. Multivalent
      2. LATAM Pediatric Vaccines Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Live Attenuated Vaccines
        2. Inactivated Vaccines
        3. Subunit Vaccines
        4. Toxoid Vaccines
        5. Conjugate Vaccines
        6. Others
      3. LATAM Pediatric Vaccines Market By Application 2022-2034 (USD MILLION/ Units)
        1. Infectious Disease
        2. Cancer
        3. Allergy
        4. Pneumococcal Diseases
        5. Influenza
        6. Measles, Mumps, and Rubella (MMR)
        7. Others
      4. Brazil
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      5. Mexico
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      6. Argentina
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      7. Chile
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      8. Colombia
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
      9. Rest of LATAM
        1. Monovalent
        2. Multivalent
        3. Live Attenuated Vaccines
        4. Inactivated Vaccines
        5. Subunit Vaccines
        6. Toxoid Vaccines
        7. Conjugate Vaccines
        8. Others
        9. Infectious Disease
        10. Cancer
        11. Allergy
        12. Pneumococcal Diseases
        13. Influenza
        14. Measles, Mumps, and Rubella (MMR)
        15. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.